Symbols / KNSA Stock $42.76 -0.65% Kiniksa Pharmaceuticals International, plc
KNSA (Stock) Chart
About
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Stock Fundamentals
Scroll to Statements| Market Cap | 3.27B | Enterprise Value | 2.89B | Income | 59.01M | Sales | 677.56M | Book/sh | 7.44 | Cash/sh | 5.41 |
| Dividend Yield | — | Payout | 0.00% | Employees | 366 | IPO | — | P/E | 57.01 | Forward P/E | 28.96 |
| PEG | — | P/S | 4.83 | P/B | 5.75 | P/C | — | EV/EBITDA | 36.68 | EV/Sales | 4.26 |
| Quick Ratio | 3.09 | Current Ratio | 3.79 | Debt/Eq | 1.67 | LT Debt/Eq | — | EPS (ttm) | 0.75 | EPS next Y | 1.48 |
| EPS Growth | — | Revenue Growth | 65.00% | Earnings | 2026-04-28 | ROA | 7.18% | ROE | 11.73% | ROIC | — |
| Gross Margin | 54.66% | Oper. Margin | 9.78% | Profit Margin | 8.71% | Shs Outstand | 45.90M | Shs Float | 39.90M | Short Float | 9.62% |
| Short Ratio | 6.09 | Short Interest | — | 52W High | 50.03 | 52W Low | 20.19 | Beta | 0.06 | Avg Volume | 637.58K |
| Volume | 134.31K | Target Price | $58.00 | Recom | Strong_buy | Prev Close | $43.04 | Price | $42.76 | Change | -0.65% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-16 | main | Wedbush | Outperform → Outperform | $58 |
| 2026-02-25 | main | Wells Fargo | Overweight → Overweight | $53 |
| 2026-02-25 | main | Wedbush | Outperform → Outperform | $53 |
| 2026-02-19 | init | Canaccord Genuity | — → Buy | $62 |
| 2026-01-13 | main | Wedbush | Outperform → Outperform | $50 |
| 2025-10-29 | main | Goldman Sachs | Buy → Buy | $55 |
| 2025-10-17 | main | Citigroup | Buy → Buy | $50 |
| 2025-10-13 | main | Wedbush | Outperform → Outperform | $44 |
| 2025-09-29 | init | TD Cowen | — → Buy | $60 |
| 2025-09-25 | main | Wells Fargo | Overweight → Overweight | $45 |
| 2025-07-29 | main | Jefferies | Buy → Buy | $54 |
| 2025-07-09 | main | Wells Fargo | Overweight → Overweight | $42 |
| 2025-04-29 | main | Jefferies | Buy → Buy | $45 |
| 2025-04-16 | reit | Wedbush | Outperform → Outperform | $34 |
| 2025-03-13 | init | Citigroup | — → Buy | $40 |
| 2024-11-05 | main | JP Morgan | Overweight → Overweight | $40 |
| 2024-10-30 | main | Evercore ISI Group | Outperform → Outperform | $35 |
| 2024-07-23 | main | Wedbush | Outperform → Outperform | $34 |
| 2024-05-03 | init | Wells Fargo | — → Overweight | $34 |
| 2024-05-01 | main | JP Morgan | Overweight → Overweight | $30 |
- Kiniksa Pharmaceuticals International PLC (KNSA) Stock Down 5.5% -- Now Undervalued? GF Score: 57/100 - GuruFocus ue, 21 Apr 2026 01
- KNSA (Kiniksa Pharmaceuticals International plc) posts steep Q4 2025 EPS miss, sending shares down 2.2% in today’s trading session. - Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 01
- Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month - Sahm Wed, 22 Apr 2026 19
- Understanding the Setup: (KNSA) and Scalable Risk - Stock Traders Daily Wed, 22 Apr 2026 03
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Trading Down 4.3% - Here's What Happened - MarketBeat Mon, 20 Apr 2026 17
- What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge - The Motley Fool Fri, 17 Apr 2026 21
- Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Stock Price Today & Analysis - Gotrade hu, 15 Jan 2026 01
- Kiniksa (KNSA) Stock: Why It Could Continue (Drifts Lower) 2026-04-15 - Trending Volume Leaders - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 15 Apr 2026 20
- Kiniksa Pharmaceuticals (KNSA) Shows High Growth Momentum and Technical Breakout Potential - ChartMill ue, 14 Apr 2026 10
- $KNSA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 08
- Kiniksa targets 40,000 U.S. patients with new ARCALYST TV ads - Stock Titan Wed, 08 Apr 2026 07
- Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates - Yahoo Finance ue, 24 Feb 2026 08
- Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat Fri, 17 Apr 2026 09
- COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan - Stock Titan Mon, 13 Apr 2026 07
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat Sat, 18 Apr 2026 05
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
677.56
+60.09%
|
423.24
+56.60%
|
270.26
+22.74%
|
220.18
|
| Operating Revenue |
|
677.56
+60.09%
|
423.24
+56.60%
|
270.26
+22.74%
|
220.18
|
| Cost Of Revenue |
|
307.22
+404.38%
|
60.91
+82.33%
|
33.41
+45.91%
|
22.89
|
| Reconciled Cost Of Revenue |
|
307.22
+404.38%
|
60.91
+82.33%
|
33.41
+45.91%
|
22.89
|
| Gross Profit |
|
370.35
+2.21%
|
362.33
+52.98%
|
236.85
+20.06%
|
197.28
|
| Operating Expense |
|
293.12
-28.15%
|
407.94
+55.68%
|
262.05
+39.75%
|
187.51
|
| Research And Development |
|
96.85
-13.23%
|
111.62
+46.69%
|
76.10
+16.20%
|
65.49
|
| Selling General And Administration |
|
196.27
+16.82%
|
168.01
+29.81%
|
129.43
+32.13%
|
97.95
|
| Other Operating Expenses |
|
—
|
128.31
+127.00%
|
56.52
+134.82%
|
24.07
|
| Total Expenses |
|
600.34
+28.04%
|
468.86
+58.69%
|
295.45
+40.42%
|
210.41
|
| Operating Income |
|
77.22
+269.28%
|
-45.62
-81.04%
|
-25.20
-357.81%
|
9.77
|
| Total Operating Income As Reported |
|
77.22
+269.28%
|
-45.62
-81.04%
|
-25.20
-357.81%
|
9.77
|
| EBITDA |
|
78.78
+279.36%
|
-43.92
-92.17%
|
-22.86
-287.72%
|
12.18
|
| Normalized EBITDA |
|
78.78
+279.36%
|
-43.92
-92.17%
|
-22.86
-287.72%
|
12.18
|
| Reconciled Depreciation |
|
1.55
-8.32%
|
1.70
-27.60%
|
2.34
-2.54%
|
2.40
|
| EBIT |
|
77.22
+269.28%
|
-45.62
-81.04%
|
-25.20
-357.81%
|
9.77
|
| Net Income |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Pretax Income |
|
88.87
+345.82%
|
-36.15
-117.10%
|
-16.65
-251.02%
|
11.03
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
—
|
1.25
|
| Net Interest Income |
|
—
|
—
|
—
|
1.25
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
1.25
|
| Interest Income |
|
—
|
—
|
—
|
1.25
|
| Other Income Expense |
|
11.65
+23.07%
|
9.46
+10.77%
|
8.54
+581.88%
|
1.25
|
| Other Non Operating Income Expenses |
|
11.65
+23.07%
|
9.46
+10.77%
|
8.54
+581.88%
|
1.25
|
| Tax Provision |
|
29.86
+324.13%
|
7.04
+122.91%
|
-30.74
+82.17%
|
-172.34
|
| Tax Rate For Calcs |
|
0.00
+60.02%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Net Income From Continuing Operation Net Minority Interest |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Net Income From Continuing And Discontinued Operation |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Net Income Continuous Operations |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Normalized Income |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Net Income Common Stockholders |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Diluted EPS |
|
—
|
-0.60
-400.00%
|
0.20
-92.31%
|
2.60
|
| Basic EPS |
|
—
|
-0.60
-400.00%
|
0.20
-92.42%
|
2.64
|
| Basic Average Shares |
|
—
|
71.42
+1.95%
|
70.06
+0.98%
|
69.38
|
| Diluted Average Shares |
|
—
|
71.42
-0.69%
|
71.92
+2.13%
|
70.42
|
| Diluted NI Availto Com Stockholders |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
763.63
+31.54%
|
580.55
+10.30%
|
526.32
+14.50%
|
459.67
|
| Current Assets |
|
527.18
+58.88%
|
331.80
+20.09%
|
276.30
+13.67%
|
243.06
|
| Cash Cash Equivalents And Short Term Investments |
|
414.07
+69.96%
|
243.63
+18.05%
|
206.37
+8.27%
|
190.61
|
| Cash And Cash Equivalents |
|
165.60
-9.80%
|
183.58
+70.05%
|
107.95
-12.03%
|
122.72
|
| Other Short Term Investments |
|
248.48
+313.81%
|
60.05
-38.99%
|
98.42
+44.96%
|
67.89
|
| Receivables |
|
15.59
-62.63%
|
41.72
+96.20%
|
21.27
+4.68%
|
20.32
|
| Accounts Receivable |
|
15.59
-62.63%
|
41.72
+96.20%
|
21.27
+67.98%
|
12.66
|
| Other Receivables |
|
—
|
—
|
—
|
7.66
|
| Inventory |
|
54.90
+108.22%
|
26.36
-15.29%
|
31.12
+44.09%
|
21.60
|
| Raw Materials |
|
9.97
-0.04%
|
9.97
|
0.00
|
0.00
|
| Work In Process |
|
29.40
|
0.00
-100.00%
|
18.26
+189.26%
|
6.31
|
| Finished Goods |
|
20.55
-3.25%
|
21.25
+65.16%
|
12.86
-15.85%
|
15.29
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
42.61
+112.18%
|
20.08
+14.52%
|
17.54
+66.44%
|
10.54
|
| Total Non Current Assets |
|
236.46
-4.94%
|
248.75
-0.51%
|
250.03
+15.43%
|
216.61
|
| Net PPE |
|
11.75
+6.45%
|
11.04
-12.85%
|
12.66
+79.82%
|
7.04
|
| Gross PPE |
|
18.98
-1.31%
|
19.23
-5.96%
|
20.45
+47.10%
|
13.90
|
| Accumulated Depreciation |
|
-7.23
+11.75%
|
-8.19
-5.24%
|
-7.79
-13.50%
|
-6.86
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.27
-51.42%
|
0.56
-6.80%
|
0.60
+5.98%
|
0.57
|
| Construction In Progress |
|
0.26
+64.52%
|
0.15
+1092.31%
|
0.01
|
0.00
|
| Other Properties |
|
13.81
-5.28%
|
14.58
-8.30%
|
15.90
+69.14%
|
9.40
|
| Leases |
|
4.64
+18.01%
|
3.93
+0.00%
|
3.93
+0.00%
|
3.93
|
| Goodwill And Other Intangible Assets |
|
15.25
-6.15%
|
16.25
-5.80%
|
17.25
-5.48%
|
18.25
|
| Other Intangible Assets |
|
15.25
-6.15%
|
16.25
-5.80%
|
17.25
-5.48%
|
18.25
|
| Non Current Deferred Assets |
|
198.15
-6.16%
|
211.15
-3.71%
|
219.28
+18.22%
|
185.50
|
| Non Current Deferred Taxes Assets |
|
198.15
-6.16%
|
211.15
-3.71%
|
219.28
+18.22%
|
185.50
|
| Other Non Current Assets |
|
11.31
+9.62%
|
10.31
+1147.28%
|
0.83
-85.80%
|
5.82
|
| Total Liabilities Net Minority Interest |
|
196.03
+37.93%
|
142.12
+62.45%
|
87.48
+37.72%
|
63.52
|
| Current Liabilities |
|
139.18
+38.33%
|
100.62
+58.05%
|
63.67
+35.27%
|
47.07
|
| Payables And Accrued Expenses |
|
92.63
+41.40%
|
65.50
+77.24%
|
36.96
+37.92%
|
26.80
|
| Payables |
|
2.03
-0.54%
|
2.04
-75.27%
|
8.25
+4.39%
|
7.90
|
| Accounts Payable |
|
2.03
-0.54%
|
2.04
-75.27%
|
8.25
+4.39%
|
7.90
|
| Current Accrued Expenses |
|
90.60
+42.75%
|
63.47
+121.04%
|
28.71
+51.93%
|
18.90
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
21.44
+25.76%
|
17.05
+6.84%
|
15.95
+42.28%
|
11.21
|
| Current Debt And Capital Lease Obligation |
|
2.99
+49.87%
|
1.99
-11.54%
|
2.25
-31.75%
|
3.30
|
| Current Capital Lease Obligation |
|
2.99
+49.87%
|
1.99
-11.54%
|
2.25
-31.75%
|
3.30
|
| Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.31
|
0.00
|
| Current Deferred Revenue |
|
—
|
0.00
-100.00%
|
0.31
|
0.00
|
| Other Current Liabilities |
|
22.13
+37.67%
|
16.08
+96.23%
|
8.19
+42.39%
|
5.75
|
| Total Non Current Liabilities Net Minority Interest |
|
56.84
+36.98%
|
41.50
+74.23%
|
23.82
+44.72%
|
16.46
|
| Long Term Debt And Capital Lease Obligation |
|
6.51
-17.20%
|
7.86
-21.42%
|
10.01
+282.16%
|
2.62
|
| Long Term Capital Lease Obligation |
|
6.51
-17.20%
|
7.86
-21.42%
|
10.01
+282.16%
|
2.62
|
| Non Current Deferred Liabilities |
|
31.81
+0.00%
|
31.81
+166.11%
|
11.95
-0.38%
|
12.00
|
| Non Current Deferred Revenue |
|
31.81
+0.00%
|
31.81
+166.11%
|
11.95
-0.38%
|
12.00
|
| Other Non Current Liabilities |
|
18.52
+916.02%
|
1.82
-1.88%
|
1.86
+1.03%
|
1.84
|
| Stockholders Equity |
|
567.61
+29.46%
|
438.44
-0.09%
|
438.84
+10.78%
|
396.15
|
| Common Stock Equity |
|
567.61
+29.46%
|
438.44
-0.09%
|
438.84
+10.78%
|
396.15
|
| Capital Stock |
|
0.02
+5.00%
|
0.02
+0.00%
|
0.02
+5.26%
|
0.02
|
| Common Stock |
|
0.02
+5.00%
|
0.02
+0.00%
|
0.02
+5.26%
|
0.02
|
| Share Issued |
|
76.29
+5.21%
|
72.52
+2.92%
|
70.46
+1.09%
|
69.70
|
| Ordinary Shares Number |
|
76.29
+5.21%
|
72.52
+2.92%
|
70.46
+1.09%
|
69.70
|
| Additional Paid In Capital |
|
1,029.75
+7.30%
|
959.72
+4.69%
|
916.76
+3.23%
|
888.12
|
| Retained Earnings |
|
-462.14
+11.32%
|
-521.14
-9.04%
|
-477.95
+2.86%
|
-492.03
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.03
+84.66%
|
-0.16
-2816.67%
|
0.01
-86.36%
|
0.04
|
| Other Equity Adjustments |
|
-0.03
+84.66%
|
-0.16
-2816.67%
|
0.01
-86.36%
|
0.04
|
| Total Equity Gross Minority Interest |
|
567.61
+29.46%
|
438.44
-0.09%
|
438.84
+10.78%
|
396.15
|
| Total Capitalization |
|
567.61
+29.46%
|
438.44
-0.09%
|
438.84
+10.78%
|
396.15
|
| Working Capital |
|
387.99
+67.83%
|
231.18
+8.72%
|
212.63
+8.49%
|
195.99
|
| Invested Capital |
|
567.61
+29.46%
|
438.44
-0.09%
|
438.84
+10.78%
|
396.15
|
| Total Debt |
|
9.50
-3.63%
|
9.86
-19.60%
|
12.26
+107.10%
|
5.92
|
| Capital Lease Obligations |
|
9.50
-3.63%
|
9.86
-19.60%
|
12.26
+107.10%
|
5.92
|
| Net Tangible Assets |
|
552.36
+30.83%
|
422.19
+0.14%
|
421.59
+11.56%
|
377.90
|
| Tangible Book Value |
|
552.36
+30.83%
|
422.19
+0.14%
|
421.59
+11.56%
|
377.90
|
| Inventories Adjustments Allowances |
|
-5.03
-3.56%
|
-4.85
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
137.99
+437.14%
|
25.69
+93.14%
|
13.30
+129.05%
|
5.81
|
| Cash Flow From Continuing Operating Activities |
|
137.99
+437.14%
|
25.69
+93.14%
|
13.30
+129.05%
|
5.81
|
| Net Income From Continuing Operations |
|
59.01
+236.61%
|
-43.19
-406.68%
|
14.08
-92.32%
|
183.36
|
| Depreciation Amortization Depletion |
|
1.55
-8.32%
|
1.70
-27.60%
|
2.34
-2.54%
|
2.40
|
| Depreciation And Amortization |
|
1.55
-8.32%
|
1.70
-27.60%
|
2.34
-2.54%
|
2.40
|
| Other Non Cash Items |
|
3.67
+16.90%
|
3.14
+2.69%
|
3.05
+0.43%
|
3.04
|
| Stock Based Compensation |
|
37.00
+20.56%
|
30.69
+13.05%
|
27.15
+8.08%
|
25.12
|
| Deferred Tax |
|
13.00
+59.89%
|
8.13
+124.07%
|
-33.79
+81.78%
|
-185.50
|
| Deferred Income Tax |
|
13.00
+59.89%
|
8.13
+124.07%
|
-33.79
+81.78%
|
-185.50
|
| Operating Gains Losses |
|
-0.12
-400.00%
|
-0.02
-113.41%
|
0.18
+442.42%
|
0.03
|
| Gain Loss On Sale Of PPE |
|
-0.12
-400.00%
|
-0.02
-113.41%
|
0.18
+442.42%
|
0.03
|
| Change In Working Capital |
|
24.79
-0.07%
|
24.81
+1737.70%
|
1.35
+105.98%
|
-22.57
|
| Change In Receivables |
|
26.13
+227.73%
|
-20.46
-2053.47%
|
-0.95
+94.18%
|
-16.33
|
| Changes In Account Receivables |
|
26.13
+227.73%
|
-20.46
-137.72%
|
-8.61
+0.80%
|
-8.68
|
| Change In Inventory |
|
-28.53
-699.64%
|
4.76
+149.96%
|
-9.52
+46.87%
|
-17.92
|
| Change In Prepaid Assets |
|
-22.48
-729.56%
|
-2.71
+61.65%
|
-7.07
-83.18%
|
-3.86
|
| Change In Payables And Accrued Expense |
|
37.64
+0.58%
|
37.42
+116.48%
|
17.29
+644.49%
|
2.32
|
| Change In Accrued Expense |
|
37.50
-14.25%
|
43.73
+158.14%
|
16.94
+556.73%
|
-3.71
|
| Change In Payable |
|
0.14
+102.25%
|
-6.31
-1917.29%
|
0.35
-94.25%
|
6.03
|
| Change In Account Payable |
|
0.14
+102.25%
|
-6.31
-1917.29%
|
0.35
-94.25%
|
6.03
|
| Change In Other Working Capital |
|
—
|
19.55
+7390.42%
|
0.26
-97.82%
|
12.00
|
| Change In Other Current Assets |
|
-1.21
+87.57%
|
-9.73
-312.37%
|
4.58
+72.72%
|
2.65
|
| Change In Other Current Liabilities |
|
13.24
+429.53%
|
-4.02
-23.97%
|
-3.24
-125.45%
|
-1.44
|
| Investing Cash Flow |
|
-188.99
-601.68%
|
37.67
+227.46%
|
-29.56
-265.90%
|
-8.08
|
| Cash Flow From Continuing Investing Activities |
|
-188.99
-601.68%
|
37.67
+227.46%
|
-29.56
-265.90%
|
-8.08
|
| Net PPE Purchase And Sale |
|
-1.57
-522.22%
|
-0.25
-93.85%
|
-0.13
-828.57%
|
-0.01
|
| Purchase Of PPE |
|
-1.57
-466.06%
|
-0.28
-113.08%
|
-0.13
-23.81%
|
-0.10
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.03
|
0.00
-100.00%
|
0.09
|
| Capital Expenditure |
|
-1.57
-466.06%
|
-0.28
-113.08%
|
-0.13
-23.81%
|
-0.10
|
| Net Investment Purchase And Sale |
|
-187.43
-594.21%
|
37.92
+228.87%
|
-29.43
-264.92%
|
-8.06
|
| Purchase Of Investment |
|
-386.92
-91.53%
|
-202.01
+1.42%
|
-204.93
-50.84%
|
-135.86
|
| Sale Of Investment |
|
199.49
-16.86%
|
239.94
+36.71%
|
175.51
+37.33%
|
127.80
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Financing Cash Flow |
|
33.02
+169.22%
|
12.27
+720.47%
|
1.50
-40.58%
|
2.52
|
| Cash Flow From Continuing Financing Activities |
|
33.02
+169.22%
|
12.27
+720.47%
|
1.50
-40.58%
|
2.52
|
| Net Common Stock Issuance |
|
-7.73
-55.10%
|
-4.98
-125.93%
|
-2.21
-144.84%
|
-0.90
|
| Common Stock Payments |
|
-7.73
-55.10%
|
-4.98
-125.93%
|
-2.21
-144.84%
|
-0.90
|
| Repurchase Of Capital Stock |
|
-7.73
-55.10%
|
-4.98
-125.93%
|
-2.21
-144.84%
|
-0.90
|
| Proceeds From Stock Option Exercised |
|
40.75
+136.25%
|
17.25
+366.09%
|
3.70
+8.31%
|
3.42
|
| Changes In Cash |
|
-17.98
-123.78%
|
75.63
+612.34%
|
-14.76
-6124.90%
|
0.24
|
| Beginning Cash Position |
|
183.58
+70.05%
|
107.95
-12.03%
|
122.72
+0.20%
|
122.47
|
| End Cash Position |
|
165.60
-9.80%
|
183.58
+70.05%
|
107.95
-12.03%
|
122.72
|
| Free Cash Flow |
|
136.42
+436.82%
|
25.41
+92.94%
|
13.17
+130.99%
|
5.70
|
| Income Tax Paid Supplemental Data |
|
3.01
+50.37%
|
2.00
-64.26%
|
5.61
-47.56%
|
10.69
|
| Amortization Of Securities |
|
-0.92
-307.71%
|
0.44
+141.29%
|
-1.07
-1202.44%
|
-0.08
|
| Common Stock Issuance |
|
—
|
—
|
—
|
3.42
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
3.42
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-13 View
- 42026-04-13 View
- 42026-04-08 View
- 42026-04-08 View
- 42026-04-08 View
- 42026-04-08 View
- 42026-04-08 View
- 42026-04-08 View
- 42026-04-08 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-03-11 View
- 42026-03-04 View
- 10-K2026-02-24 View
- 8-K2026-02-24 View
- 42026-02-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|